Xinnate raises SEK 31 million in oversubscribed share issue

1 July, 2025

New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD

27 June, 2025

Xinnate announces successful FDA meeting for TCP-25

23 May, 2025

Xinnate receives Orphan Drug Designation from US FDA for TCP-25

14 January, 2025

Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm

17 December, 2024

Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa

27 September, 2024

Xinnate presents TCP-25 data at international dermatology congress

5 September, 2024

Xinnate reports positive results from Phase 1 study with TCP-25, in patients with Epidermolysis Bullosa

7 May, 2024

Xinnate completes Phase 1a/b study with TCP-25

18 March, 2024

Xinnate secures 100 million SEK in financing and applies for a patent for the treatment of Epidermolysis Bullosa

7 February, 2024

EB 2026: 20-22 Jan 2026

ESDR MEETING: 10-13 Sep 2025

NLS Days: 13-14 Oct 2025